Allogene Therapeutics, Inc. (ALLO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.97-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Achieve revenue near $6 billion in 2026: FY26 rev $3.4B vs ~$6B target; 90d rev est -12.1%.
Allogene aims to control operating expenses within $210M-$225M in 2026. The company recently appointed a new CEO to drive strategy. It raised its expense guidance but shows some cost discipline. Analysts have slightly improved revenue and EPS estimates recently.
The company is still loss-making with negative EPS and cash flow. It faces revenue misses and challenges managing expenses. The termination of a key agreement and recent litigation raise risks. The stock is under pressure amid a sharp selloff.
The market reflects elevated risk and loss-making status with no clear consensus revenue growth. Recent analyst revisions are mixed but slightly improving. The price does not yet imply a durable turnaround.
Breaks if: CEO transition leads to strategic setbacks or loss of confidence
Complete leadership transition with Zachary Roberts appointed as President and CEO, succeeding David Chang.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is weakened, reflecting challenges in recent financial performance and management execution.
The market appears to price in a premium compared to peers, indicating high expectations for ALLO's future performance. However, the current valuation is seen as unjustified given the company's loss-making status and recent declines in company quality and momentum.
Fundamentals are likely to remain under pressure due to ongoing operating losses and elevated expenses. Management's focus on advancing clinical trials is progressing, but the overall financial performance has shifted to the lower half of the industry.
The thesis hinges on several factors, including the outcome of upcoming clinical trials and the potential impact of external economic conditions, such as job market trends. Additionally, the performance of sector bellwethers could influence ALLO's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own ALLO has diminished due to recent financial performance. It fell from the robust half to the weak half of its sector. The latest earnings beat and progress in the ALPHA3 trial provide some support. However, the overall standing has shifted negatively.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q2. Management announced the CEO transition with Zachary Roberts appointed as President and CEO, succeeding David Chang. This leadership change was formally disclosed in 2026-Q2 and is a one-time event with no financial metrics directly tied to it in the disclosures.
“Dr. Zachary Roberts was appointed as the new President and Chief Executive Officer, succeeding Dr. David Chang.”
Breaks if: operating expenses exceed $225 million in FY26
Breaks if: revenue falls significantly below $6 billion in FY26
In the next 1 to 3 years, ALLO faces significant challenges that could impact its growth potential. Not investment advice.